Abstract
Rhabdomyosarcomas (RMS) are rare and often lethal diseases. It is assumed that the tumor microenvironment (TME) of RMS exerts an immunosuppressive function, but there is currently no systematic analysis of the immune cells infiltrating sarcoma tissue. Focusing on two common types of RMS (alveolar [RMA] and embryonal [RME]), we performed a comprehensive immunohistochemical analysis of tumor-infiltrating immune cells in the TME. We performed a qualitative estimation of infiltrating immune cells in the tumor microenvironment by an experienced pathologist as well as a quantitative digital pathology analysis. We found that (1) manual and automatic quantification of tumor-infiltrating immune cells were consistent; (2) RME tumors showed a higher degree of immune cell infiltration than RMA tumors but (3) the number of tumor infiltrating lymphocytes was low compared to other solid tumor types; (4) microvascular density correlated with immune cell infiltration and (5) CD163 positive macrophages as well as CD54 positive microvessels were more often detected in RME than in RMA and correlated with patient overall and event free survival. Our systematic analysis provides a comprehensive view of the immune landscape of RMS which needs to be taken into account for developing immunotherapies for this rare type of cancer.
Introduction: Mapping the Immune Landscape of Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a lethal soft-tissue cancer primarily affecting children. While immunotherapy has revolutionized treatment for many adult cancers, it has seen limited success in pediatric sarcomas. This lack of efficacy is often attributed to the tumor microenvironment (TME)—the complex ecosystem of cells surrounding the tumor—which is thought to be highly immunosuppressive. However, a clear "map" of the immune cells present in RMS has been lacking.
This study compares the two main subtypes: Alveolar RMS (RMA), which is typically more aggressive, and Embryonal RMS (RME), which generally has a better prognosis. By understanding the differences in their immune landscapes, researchers aim to identify why some patients fare better and how to design more effective immunotherapies.
Methodology: Human Expertise Meets Digital Pathology
The researchers analyzed 39 patient biopsies (20 RMA and 19 RME) using a combination of traditional and digital pathology techniques. Tissue samples were stained for a wide array of markers, including T-cells (CD3, CD8), macrophages (CD68, CD163), B-cells (CD20), and blood vessel markers (CD31, CD34, CD54).
To ensure accuracy, qualitative estimates from an experienced pathologist were compared against quantitative, computer-based analysis using QuPath software. The study confirmed that digital pathology tools are highly consistent with manual pathologist assessments (p < 0.0001), supporting the use of automated tools in future sarcoma research.
Key Findings: The "Cold" Nature of RMS and the Macrophage Paradox
The analysis revealed that RMS tumors are remarkably "immunologically cold," containing significantly fewer T-cells than common adult solid tumors. This "immunological ignorance" is likely due to a low Tumor Mutational Burden (TMB); with fewer genetic mutations, the immune system is less likely to recognize the tumor as a threat.
A striking finding was the "Macrophage Paradox." In most adult cancers, a high density of CD163+ "M2" macrophages signals a poor prognosis. Surprisingly, in RME, the opposite was true: more CD163+ macrophages correlated with better survival. This suggests these cells might play a different, perhaps even anti-tumor, role in pediatric sarcomas compared to adult cancers.
Furthermore, the presence of CD54 (ICAM-1) on microvessels correlated strongly with immune cell infiltration. These vessels appear to act as "gates" that allow immune cells to enter the tumor. Conversely, the study found a near-total absence of PD-1 and PD-L1 expression, explaining why standard checkpoint inhibitor drugs have largely failed in RMS clinical trials.
Clinical Implications: Prognostic Markers
The study identified significant differences between the two subtypes. RME tumors showed higher immune cell infiltration and microvascular density than RMA tumors. Specifically:
- CD163+ Macrophages: In RME patients, a cut-off of 237 CD163+ cells per mm² was a strong predictor of survival (sensitivity 0.7, specificity 0.88).
- CD54+ Microvessels: High density of CD54+ microvessels was associated with significantly better overall survival (p=0.05) and event-free survival (p=0.02) in RME, whereas RMA tumors consistently lacked these "activated" vessels.
Conclusion and Future Directions
While limited by a small cohort size (n=39), this study provides the first systematic map of the immune landscape in RMS. The discovery that CD163+ macrophages and CD54+ microvessels are beneficial prognostic markers in RME opens new avenues for research.
Future work should investigate whether "warming up" the TME—perhaps by inducing CD54 expression on vessels—could improve immune cell recruitment. Additionally, exploring combination therapies that pair adoptive cell transfers (like CAR-T cells) with strategies to reprogram the myeloid environment could offer new hope for patients with these aggressive pediatric cancers.
Summary updated